Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt
Cancer · 2024
DOI: 10.1002/cncr.35214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Ephrem Sedeta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Brookdale University Hospital Medical Center, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, SEER Program. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: American Cancer Society.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study compared the survival of persons with secondary acute myeloid leukemia (sAML) to those with de novo AML (dnAML) by age at AML diagnosis, chemotherapy receipt, and cancer type preceding sAML diagnosis.
Methods
Data from Surveillance, Epidemiology, and End Results 17 Registries were used, which included 47,704 individuals diagnosed with AML between 2001 and 2018. Multivariable Cox proportional hazards regression was used to compare AML‐specific survival between sAML and dnAML. Trends in 5‐year age‐standardized relative survival were examined via the Joinpoint survival model.
Results
Overall, individuals with sAML had an 8% higher risk of dying from AML (hazard ratio [HR], 1.08; 95% confidence interval [CI], 1.05–1.11) compared to those with dnAML. Disparities widened with younger age at diagnosis, particularly in those who received chemotherapy for AML (HR, 1.14; 95% CI, 1.10–1.19). In persons aged 20–64 years and who received chemotherapy, HRs were greatest for those with antecedent myelodysplastic syndrome (HR, 2.04; 95% CI, 1.83–2.28), ovarian cancer (HR, 1.91; 95% CI, 1.19–3.08), head and neck cancer (HR, 1.55; 95% CI, 1.02–2.36), leukemia (HR, 1.45; 95% CI, 1.12–1.89), and non‐Hodgkin lymphoma (HR, 1.42; 95% CI, 1.20–1.69). Among those aged ≥65 years and who received chemotherapy, HRs were highest for those with antecedent cervical cancer (HR, 2.42; 95% CI, 1.15–5.10) and myelodysplastic syndrome (HR, 1.28; 95% CI, 1.19–1.38). The 5‐year relative survival improved 0.3% per year for sAML slower than 0.86% per year for dnAML. Consequently, the survival gap widened from 7.2% (95% CI, 5.4%–9.0%) during the period 2001–2003 to 14.3% (95% CI, 12.8%–15.8%) during the period 2012–2014.
Conclusions
Significant survival disparities exist between sAML and dnAML on the basis of age at diagnosis, chemotherapy receipt, and antecedent cancer, which highlights opportunities to improve outcomes among those diagnosed with sAML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Brookdale University Hospital Medical Center, Brooklyn, New York, USA.
- Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
ORCID-Profile: Ephrem Sedeta, Ahmedin Jemal, Hyuna Sung
Förderung
- American Cancer Society
Zitieren
APA
Sedeta, E., Jemal, A., Nisotel, L., & Sung, H. (2024). Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt. Cancer. https://doi.org/10.1002/cncr.35214
Vancouver
Sedeta E, Jemal A, Nisotel L, Sung H. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt. Cancer. 2024. doi:10.1002/cncr.35214
BibTeX
@article{Sedeta2024,
author = {Sedeta, Ephrem and Jemal, Ahmedin and Nisotel, Lauren and Sung, Hyuna},
title = {Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35214}
}
EUVIMED